hotspot -WSS

hotspot

author：entertainment 2025-10-01 23:05:31 - browse：4

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

WSS

Senate HELP committee spars over health care workforce policies

Biotech lab space demand falls sharply

Changes to biosimilar regulatory framework must prioritize patients

FTC loses bid to block Novant's North Carolina hospital merger

Anthony Fauci pushes back on GOP claims during Covid hearing

FTC loses bid to block Novant's North Carolina hospital merger

focus

hotspot

explore

The cancer drug shortage isn’t new — and neither are the solutions

Senate HELP committee spars over health care workforce policies

What does generative AI mean for health care? We asked experts

Lasker Awards 2023: Winners in biomedical research

Guidelines to prevent youth baseball injuries need more muscle

CDC advisers recommend seasonal use of Pfizer RSV shot

How to save PrEP access — and even expand it

Finland to offer bird flu vaccine to select groups of people, a possible global first

Medicare proposal to cover medical devices draws a mixed reaction

What Congress can do to address the rural doctor shortage

explore

Changes to biosimilar regulatory framework must prioritize patients

Readout LOUD podcast: possible new ALS drug, artificial wombs

BD to buy Edwards patient monitoring unit for $4.2 billion

Why are Kaiser Permanente staff considering a strike?

STAT wants to know your pick for a great summer read or listen

Illumina board agrees to spin off Grail, as divestment plans proceed

hotspot

hotspot

knowledge

hotspot